The European Commission has authorized expanded use of VENCLYXTO (venetoclax) in combination with acalabrutinib (with or without obinutuzumab) and with ibrutinib for treating adults with previously untreated chronic lymphocytic leukemia (CLL). Supported by Phase 3 AMPLIFY, GLOW, and Phase 2 CAPTIVATE trials, these all-oral, fixed-duration regimens offer effective, chemotherapy-free options that may allow patients treatment-free intervals. This approval extends across the EU, Iceland, Norway, and Liechtenstein, providing more targeted first-line therapies that improve progression-free survival and quality of life for CLL patients.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
